Publications

Life science alliance

Genetic and compound screens uncover factors modulating cancer cell response to indisulam.

01-09-2022

Cell discovery

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma.

23-08-2022

iScience

Identifying mutant-specific multi-drug combinations using comparative network reconstruction.

19-08-2022

Nature communications

DNA damage-induced transcription stress triggers the genome-wide degradation of promoter-bound Pol II.

24-06-2022

NPJ breast cancer

Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant.

08-06-2022

Nature reviews. Cancer

Exploiting senescence for the treatment of cancer.

01-06-2022

Cell genomics

A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer.

09-02-2022

Genome medicine

Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.

18-10-2021

Nature reviews. Gastroenterology & hepatology

Exploring liver cancer biology through functional genetic screens.

01-10-2021

Molecular cancer research : MCR

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen.

01-10-2021

Molecular oncology

Playing cancer at its own game: activating mitogenic signaling as a paradoxical intervention.

01-08-2021

Nature reviews. Clinical oncology

Precision oncology in metastatic colorectal cancer - from biology to medicine.

01-08-2021

Cell reports

The Cancer SENESCopedia: A delineation of cancer cell senescence.

27-07-2021

Nature cell biology

Publisher Correction: Elongation factor ELOF1 drives transcription-coupled repair and prevents genome instability.

01-07-2021

Nature

EGFR activation limits the response of liver cancer to lenvatinib.

01-07-2021

Nature cell biology

Elongation factor ELOF1 drives transcription-coupled repair and prevents genome instability.

01-06-2021

Cancer discovery

Thinking Differently about Cancer Treatment Regimens.

01-05-2021

The oncologist

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.

01-04-2021

Cancers

Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells.

05-03-2021

Genome medicine

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

10-02-2021

British journal of cancer

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.

01-01-2021

Cancer research

A Functional Genomic Screen Identifies the Deubiquitinase USP11 as a Novel Transcriptional Regulator of ERα in Breast Cancer.

15-11-2020

International journal of cancer

Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.

15-10-2020

eLife

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.

05-10-2020

Molecular oncology

Towards a cancer mission in Horizon Europe: recommendations.

01-08-2020

PloS one

Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.

09-07-2020

Nature communications

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.

22-06-2020

Cancer chemotherapy and pharmacology

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.

01-05-2020

British journal of cancer

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.

01-04-2020

Future oncology (London, England)

Vorinostat in patients with resistant BRAF^V600E mutated advanced melanoma: a proof of concept study.

01-04-2020

Gut

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.

01-04-2020

Future oncology (London, England)

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.

01-02-2020

Translational oncology

RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer.

01-02-2020

Nature cancer

A roadmap for the next decade in cancer research.

01-01-2020

Clinical cancer research : an official journal of the American Association for Cancer Research

BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.

01-12-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.

01-12-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.

15-11-2019

Nature

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

01-10-2019

Cancer letters

Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.

01-10-2019

The Journal of molecular diagnostics : JMD

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.

01-09-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

15-07-2019

Nature cell biology

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.

01-06-2019

Cancer research

PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer.

15-05-2019

NPJ breast cancer

Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers.

25-04-2019

Oncoimmunology

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

14-12-2018

Molecular & cellular oncology

With great power comes great vulnerability.

14-12-2018

Genome medicine

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

27-11-2018

Journal of hepatology

Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

01-11-2018

Molecular & cellular proteomics : MCP

A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.

01-10-2018

Bioinformatics (Oxford, England)

Comparative Network Reconstruction using mixed integer programming.

01-09-2018

Key Publication

Genetic and compound screens uncover factors modulating cancer cell response to indisulam.

EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma.

Identifying mutant-specific multi-drug combinations using comparative network reconstruction.

DNA damage-induced transcription stress triggers the genome-wide degradation of promoter-bound Pol II.

Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant.

Exploiting senescence for the treatment of cancer.

A large-scale organoid-based screening platform to advance drug repurposing in pancreatic cancer.

Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.

Exploring liver cancer biology through functional genetic screens.

Identification of Autophagy-Related Genes as Targets for Senescence Induction Using a Customizable CRISPR-Based Suicide Switch Screen.

Playing cancer at its own game: activating mitogenic signaling as a paradoxical intervention.

Precision oncology in metastatic colorectal cancer - from biology to medicine.

The Cancer SENESCopedia: A delineation of cancer cell senescence.

Publisher Correction: Elongation factor ELOF1 drives transcription-coupled repair and prevents genome instability.

EGFR activation limits the response of liver cancer to lenvatinib.

Elongation factor ELOF1 drives transcription-coupled repair and prevents genome instability.

Thinking Differently about Cancer Treatment Regimens.

Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer.

Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells.

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.

A Functional Genomic Screen Identifies the Deubiquitinase USP11 as a Novel Transcriptional Regulator of ERα in Breast Cancer.

Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer.

Towards a cancer mission in Horizon Europe: recommendations.

Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours.

Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer.

Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.

Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study.

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.

Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.

RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS-mutant colorectal cancer.

A roadmap for the next decade in cancer research.

BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.

Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.

POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.

Inducing and exploiting vulnerabilities for the treatment of liver cancer.

Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.

PDLIM2 Is a Marker of Adhesion and β-Catenin Activity in Triple-Negative Breast Cancer.

Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers.

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

With great power comes great vulnerability.

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.

Phospho-ERK is a biomarker of response to a synthetic lethal drug combination of sorafenib and MEK inhibition in liver cancer.

A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.

Comparative Network Reconstruction using mixed integer programming.

This site uses cookies

Vorinostat in patients with resistant BRAF^V600E mutated advanced melanoma: a proof of concept study.